سعر اونكودوكس 50 مجم فيال 2022

Oncodox 50 mg vial: doxorubicin 50 mg for intravenous use (anthracycline cytotoxic) by Cipla Ltd. (India), distributed by Star International Company; 1 vial per pack.

• Component of multiagent adjuvant chemotherapy for women with axillary lymph node involvement after resection of primary breast cancer.DailyMed (U.S. National Library of Medicine)
• Acute lymphoblastic and acute myeloblastic leukaemia, Hodgkin and non-Hodgkin lymphoma, and metastatic breast, Wilms tumour, neuroblastoma, soft tissue and bone sarcomas, ovarian, transitional cell bladder, thyroid, gastric and bronchogenic carcinomas.DailyMed (U.S. National Library of Medicine)

• Severe myocardial insufficiency; myocardial infarction within the past 4-6 weeks; severe persistent drug-induced myelosuppression; severe hepatic impairment (Child-Pugh C or bilirubin >5 mg/dL); severe hypersensitivity to doxorubicin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Cardiomyopathy risk proportional to cumulative dose (1-20% at 300-500 mg/m2); assess LVEF before, during and after treatment. Secondary AML/MDS, extravasation with severe tissue necrosis, severe myelosuppression, and embryo-fetal toxicity are boxed/major warnings.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm; advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Doxorubicin: Intercalates DNA and inhibits topoisomerase II, disrupting DNA replication and transcription; generates free radicals contributing to cytotoxicity and cardiotoxicity.